Archive November 2010

House Judiciary Subcommittee on Courts and Competition Policy Hearing

Nov30

Chairman Conyers, Ranking Member Smith and other members of the Committee, I appreciate the opportunity to come before you today and testify about antitrust enforcement in the healthcare industry. As a former antitrust enforcement official I strongly believe the mission of the Federal Trade Commission and Antitrust Division of the Department of Justice is vital […]

Senate Commerce, Science and Transportation Committee Hearing

Nov30

Mr. Chairman and Members of the Committee, I am Devon Herrick, a Senior Fellow at the National Center for Policy Analysis, a nonprofit, nonpartisan public policy research organization dedicated to developing and promoting private alternatives to government regulation and control, solving problems by relying on the strength of the competitive, entrepreneurial private sector. I welcome […]

Brigham and Women’s Hospital Makes Leapfrog Top Hospitals List

Nov30

BOSTON, Dec. 1 Brigham and Women’s Hospital issued the following news release:Brigham and Women’s Hospital (BWH) was named a 2010 Leapfrog Top Hospital. BWH is one of 65 hospitals recognized for delivering the highest quality of care in the nation while attaining the highest levels of efficiency. The Leapfrog Group devises this prestigious list from […]

Six Year Multi-Center Study Finds No Reduction in Harm Due to Medical Care

Nov30

BOSTON, Dec. 1 Brigham and Women’s Hospital issued the following news release:Researchers from Brigham and Women’s Hospital (BWH), Stanford University Medical School and the Institute for Healthcare Improvement (IHI), assessing patient safety efforts at 10 randomly selected North Carolina hospitals over a five year span, found no decrease in patient harm during that time. The […]

Researchers at SUNY Downstate Identify Rising Incidence of Valvular Heart Diseases in New York State

Nov30

BROOKLYN, N.Y., Dec. 1 SUNY Downstate Medical Center issued the following news release:The incidence of hospitalization and treatment for heart valve diseases in New York State has constantly and progressively risen since the early 1980s, according to research presented at the recent meeting of the American Heart Association (AHA) by SUNY Downstate Medical Center. The […]

AHA Statement on the Final Report from the National Commission on Fiscal Responsibility

Nov30

WASHINGTON, Dec. 1 The American Hospital Association issued the following news release:Rich UmbdenstockPresident and CEOAmerican Hospital AssociationIt is never an easy task to tackle the deficit and we appreciate the hard work of the commission as they have taken on the challenge.Today’s final report contains recommendations that could jeopardize hospital services for vulnerable patients and […]

FDA wants more data on Valeant-Glaxo epilepsy drug

Nov30

NEW YORK Valeant Pharmaceuticals International Inc. and GlaxoSmithKline PLC said Wednesday that the Food and Drug Administration did not approve their epilepsy drug candidate ezogabine.The companies said the FDA cited "non-clinical reasons" in declining to approve ezogabine. They said they are reviewing the FDA’s response to their application, and plan to answer the FDA in […]

Meda: Complete Response letter for ezogabine

Nov30

STOCKHOLM, Sweden(BUSINESS WIRE) Regulatory News: Valeant Pharmaceuticals International, (Meda’s (STO:MEDAA) partner for ezogabine – known as retigabine outside of the U.S.) has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ezogabine. Ezogabine is an investigational anti-epileptic drug being studied for the adjunctive treatment […]

GSK and Valeant Announce Receipt of U.S. FDA Complete Response Letter for ezogabine

Nov30

<< >>LONDON, RESEARCH TRIANGLE PARK, N.C., and MISSISSAUGA, Ontario, Dec. 1 /CNW/ GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX; TSX) announced receipt of a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ezogabine, an investigational anti-epileptic drug being studied for the adjunctive […]

Complete Response letter for ezogabine

Nov30

Complete Response letter for ezogabineValeant Pharmaceuticals International, (Meda’s partner for ezogabine – known as retigabine outside of the U.S.) has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ezogabine. Ezogabine is an investigational anti-epileptic drug being studied for the adjunctive treatment of adults […]